Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site ...
The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company’s 2031 sales target.
July 28 (Reuters) - GSK on Tuesday beat second-quarter profit expectations and launched a £1.9 billion ($2.52 billion) cost savings drive as the British drugmaker seeks to ramp up its development ...
GSK is shutting a research and development hub in cost-cutting plans. The pharma development firm is set to shut a Stevenage… | Health | London | Medical | National | Investment | Pharmaceuticals | He ...
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results